AB
LCTX icon

Amalgamated Bank’s Lineage Cell Therapeutics LCTX Stock Holding History

Amalgamated Bank’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-4,351
Closed -$2K – 3076
2025
Q1 		$2K Hold
4,351
– – ﹤0.01% 2850
2024
Q4 		$2K Hold
4,351
– – ﹤0.01% 2908
2024
Q3 		$4K Hold
4,351
– – ﹤0.01% 2823
2024
Q2 		$4K Hold
4,351
– – ﹤0.01% 2858
2024
Q1 		$6K Sell
4,351
-13,919
-76% -$15.8K ﹤0.01% 2650
2023
Q4 		$20K Sell
18,270
-1,295
-7% -$1.42K ﹤0.01% 2646
2023
Q3 		$23K Hold
19,565
– – ﹤0.01% 2585
2023
Q2 		$28K Buy
+19,565
New +$27K ﹤0.01% 2572
2022
Q2 		– Sell
-15,165
Closed -$23K – 3129
2022
Q1 		$23K Sell
15,165
-1,141
-7% -$1.77K ﹤0.01% 2758
2021
Q4 		$40K Sell
16,306
-237
-1% -$555 ﹤0.01% 2117
2021
Q3 		$42K Sell
16,543
-524
-3% -$1.34K ﹤0.01% 2140
2021
Q2 		$49K Buy
+17,067
New +$44.2K ﹤0.01% 2165
2020
Q2 		– Sell
-15,254
Closed -$13K – 1573
2020
Q1 		$13K Sell
15,254
-1,197
-7% -$1.19K ﹤0.01% 1641
2019
Q4 		$15K Buy
16,451
+1,903
+13% +$1.58K ﹤0.01% 1834
2019
Q3 		$14K Sell
14,548
-180
-1% -$186 ﹤0.01% 1763
2019
Q2 		$16K Buy
14,728
+1,859
+14% +$2.14K ﹤0.01% 1794
2019
Q1 		$17K Buy
12,869
+597
+5% +$743 ﹤0.01% 1685
2018
Q4 		$11K Buy
12,272
+833
+7% +$1.28K ﹤0.01% 1624
2018
Q3 		$24K Sell
11,439
-2,834
-20% -$5.95K ﹤0.01% 1433
2018
Q2 		$26K Buy
14,273
+1,535
+12% +$3.09K ﹤0.01% 1731
2018
Q1 		$30K Sell
12,738
-280
-2% -$657 ﹤0.01% 1597
2017
Q4 		$24K Buy
+13,018
New +$28.4K ﹤0.01% 1642

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Amalgamated Bank's LCTX Position: Q2 2025 in Review

Amalgamated Bank sold out of Lineage Cell Therapeutics (LCTX) in Q2 2025, closing a stake of 4,351 shares — an estimated $2K sold.

Amalgamated Bank first reported a position in LCTX in Q4 2017 and held it in 22 quarters. The position peaked at $49K in Q2 2021. 129 funds tracked by Wall St. Rank hold LCTX as of Q2 2025.

  • Amalgamated Bank reported no remaining Lineage Cell Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Amalgamated Bank sold 4,351 Lineage Cell Therapeutics shares in Q2 2025, an estimated $2K.
  • Amalgamated Bank first reported a position in Lineage Cell Therapeutics in Q4 2017 and held it in 22 quarters.
  • Amalgamated Bank's Lineage Cell Therapeutics position peaked at $49K in Q2 2021.
  • 129 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2025.

Based on Amalgamated Bank's 13F filing for Q2 2025, filed 4 Aug 2025.